Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ginger D Constantine

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
The Journal of Sexual Medicine|October 4, 2016
TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE TrialSheryl A Kingsberg, Leonard Derogatis, James A Simon, et al.
Current Medical Research and Opinion|October 3, 2013
Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophyGinger D Constantine, Nico Bruyniks, Nicole Princic, et al.
Menopause (New York, N.Y.)|December 22, 2016
TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiolDavid F Archer, Ginger D Constantine, James A Simon, et al.
Journal of Pharmaceutical Sciences|April 9, 2019
Pharmacokinetics and Tolerability of a Novel 17β-Estradiol and Progesterone Intravaginal Ring in SheepHerman Weiss, Bridget Martell, Ginger D Constantine, et al.
Contraception|December 14, 2011
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndromeEllen W Freeman, Uriel Halbreich, Gary S Grubb, et al.
Menopause (New York, N.Y.)|January 30, 2019
Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)Rogerio A Lobo, James Liu, Frank Z Stanczyk, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|March 23, 2011
Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of useMandana Rad, Cornelis Kluft, Marieke L de Kam, et al.
Menopause (New York, N.Y.)|June 24, 2009
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosisJoAnn V Pinkerton, David F Archer, Wulf H Utian, et al.
Maturitas|April 3, 2017
A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data reviewJames A Simon, David F Archer, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|October 28, 2020
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trialGinger D Constantine, James A Simon, Andrew M Kaunitz, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
The Journal of Sexual Medicine|October 4, 2016
TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE TrialSheryl A Kingsberg, Leonard Derogatis, James A Simon, et al.
Current Medical Research and Opinion|October 3, 2013
Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophyGinger D Constantine, Nico Bruyniks, Nicole Princic, et al.
Menopause (New York, N.Y.)|December 22, 2016
TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiolDavid F Archer, Ginger D Constantine, James A Simon, et al.
Journal of Pharmaceutical Sciences|April 9, 2019
Pharmacokinetics and Tolerability of a Novel 17β-Estradiol and Progesterone Intravaginal Ring in SheepHerman Weiss, Bridget Martell, Ginger D Constantine, et al.
Contraception|December 14, 2011
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndromeEllen W Freeman, Uriel Halbreich, Gary S Grubb, et al.
Menopause (New York, N.Y.)|January 30, 2019
Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)Rogerio A Lobo, James Liu, Frank Z Stanczyk, et al.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|March 23, 2011
Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of useMandana Rad, Cornelis Kluft, Marieke L de Kam, et al.
Menopause (New York, N.Y.)|June 24, 2009
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosisJoAnn V Pinkerton, David F Archer, Wulf H Utian, et al.
Maturitas|April 3, 2017
A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data reviewJames A Simon, David F Archer, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|October 28, 2020
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trialGinger D Constantine, James A Simon, Andrew M Kaunitz, et al.
Pageof 5